Please login to the form below

Not currently logged in
Email:
Password:

S-A in informal talks to acquire Genzyme

French drugmaker sanofi-aventis has approached Genzyme regarding a potential acquisition, according to a "reliable" source

French drugmaker sanofi-aventis (S-A) has approached Genzyme regarding a potential acquisition, according to a "reliable" source.

It is thought that S-A started informal talks with Genzyme, the largest maker of medicines for genetic diseases, about two weeks ago. The talks remain at an early stage and issues such as price and management have yet to be discussed.

Acquiring Genzyme would help S-A expand in biotechnology. Earlier this month, sources suggested S-A was planning an acquisition in the US that may be worth $20bn or more, but declined to be specific.

At the time, analysts cited Genzyme as a potential target for a takeover as well as Allegan and Biogen Idec.

Genzyme's current market capitalisation is close to $14bn.

Shares in the biotech firm climbed 21 per cent on the news of the talks, marking the largest stock price increase for Genzyme in more than a decade.

26th July 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...